Alzheimer's Neurotechnology and Neuromodulation Companies

Overview

This category covers companies developing neurotechnology and neuromodulation devices for Alzheimer's disease (AD) and related neurodegenerative conditions. These technologies include brain-computer interfaces (BCI), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and neuroprosthetics aimed at cognitive enhancement, memory support, and disease modification.

Neurotechnology represents a promising frontier for Alzheimer's treatment, offering non-pharmacological approaches to modulate neural circuits, enhance cognitive function, and potentially slow disease progression. While many of these technologies are still in development, several companies have received FDA breakthrough device designations and are actively conducting clinical trials[@neurotechnology2024].

Brain-Computer Interface (BCI) Companies

BCI technology enables direct communication between neural devices and external systems, with emerging applications for Alzheimer's disease including cognitive monitoring, memory enhancement, and neural circuit modulation.

Invasive BCI Companies

Overview

This category covers companies developing neurotechnology and neuromodulation devices for Alzheimer's disease (AD) and related neurodegenerative conditions. These technologies include brain-computer interfaces (BCI), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and neuroprosthetics aimed at cognitive enhancement, memory support, and disease modification.

Neurotechnology represents a promising frontier for Alzheimer's treatment, offering non-pharmacological approaches to modulate neural circuits, enhance cognitive function, and potentially slow disease progression. While many of these technologies are still in development, several companies have received FDA breakthrough device designations and are actively conducting clinical trials[@neurotechnology2024].

Brain-Computer Interface (BCI) Companies

BCI technology enables direct communication between neural devices and external systems, with emerging applications for Alzheimer's disease including cognitive monitoring, memory enhancement, and neural circuit modulation.

Invasive BCI Companies

| Company | Product | Technology | AD Application | Status |
|---------|---------|------------|----------------|--------|
| [Neuralink](/companies/neuralink) | N1 Implant | 1,024+ electrode array | Memory restoration, neural recording | Human trials (PRIME Study) |
| [Synchron](/companies/synchron) | Stentrode | Endovascular stent-array | Motor/cognitive interface | Phase 1 COMMANDER |
| [Blackrock Neurotech](/companies/blackrock-neurotech) | Utah Array | Intracortical microelectrode | Neural prosthetics research | Clinical |
| [Precision Neuroscience](/companies/precision-neuroscience) | Layer 7 Cortical Interface | Surface ECoG array | Epilepsy/cognitive mapping | Phase 1 |
| [Paradromics](/companies/paradromics) | Connexus DDI | High-bandwidth intracortical | Communication restoration | Preclinical |

Non-Invasive BCI Companies

| Company | Product | Technology | AD Application | Status |
|---------|---------|------------|----------------|--------|
| [EMOTIV](/companies/emotiv) | EPOC+ | 14-channel EEG | Cognitive monitoring | Commercial |
| [g.tec](/companies/gtec) | g.HIamp | 64-256 channel EEG | Research-grade recording | Commercial |
| [BrainCo](/companies/brainco) | Focus | EEG headband | Cognitive training | Commercial |
| [Bitbrain](/companies/bitbrain) | EPOC | EEG wearable | BCI applications | Commercial |
| [Kernel](/companies/kernel) | Flow | Non-invasive hemodynamic | Cognitive enhancement | Development |

Deep Brain Stimulation (DBS) Companies

DBS uses implanted electrodes to modulate specific brain regions. For Alzheimer's, targets include the fornix, nucleus basalis of Meynert, and entorhinal cortex. Several companies provide DBS systems approved for Parkinson's disease that are being investigated for AD applications.

DBS System Manufacturers

| Company | Products | AD Research Focus | Status |
|---------|----------|------------------|--------|
| [Medtronic](/companies/medtronic) | Activa PC, RC+S | Fornix stimulation, memory | Investigational |
| [Boston Scientific](/companies/boston-scientific) | Vercise Gevia, Genus | Neural network modulation | Investigational |
| [Abbott](/companies/abbott) | Infinity DBS | Directional stimulation | Research |
| LivaNova | Sentia | DBS system | Research |

Research and Development

• Medtronic AD Research: Medtronic has conducted clinical trials investigating DBS of the fornix and nucleus basalis of Meynert for mild cognitive impairment and Alzheimer's disease. The FORESTMEC trial explored memory enhancement in AD patients[@medtronic2023].
• Boston Scientific: Developing next-generation directional DBS leads that can selectively target neural circuits while minimizing side effects.
• Abbott: Their Infinity system with directional leads is being studied for cognitive applications.

Transcranial Magnetic Stimulation (TMS) Companies

TMS uses magnetic fields to stimulate nerve cells in the brain. Several companies provide FDA-approved TMS systems for depression that are being investigated for cognitive enhancement in AD.

TMS System Manufacturers

| Company | Products | AD Application | Status |
|---------|----------|----------------|--------|
| Nexstim | eXimia NBS | Navigated TMS, cognitive mapping | Research |
| MagVenture | MagPro X100 | rTMS for cognition | Clinical |
| Magstim | Rapid2 | rTMS coil systems | Clinical |
| BrainWay | Deep TMS | Deep brain stimulation | Clinical |

Transcranial Direct Current Stimulation (tDCS) Companies

tDCS uses low electrical currents to modulate brain activity. It's being investigated as a non-invasive approach to enhance memory and cognitive function in Alzheimer's patients.

tDCS Device Manufacturers

| Company | Products | AD Application | Status |
|---------|----------|----------------|--------|
| Soterix Medical | tDCS | tDCS devices | Investigational |
| Neuroelectrics | Starstim | tDCS/tACS | Research |
| BrainTech | tDCS headset | Cognitive enhancement | Consumer |

Neuroprosthetics and Memory Devices

Emerging neuroprosthetic technologies aim to restore or enhance memory function in Alzheimer's patients by interfacing directly with neural circuits.

Companies Developing Memory Prosthetics

| Company | Technology | Target | Status |
|---------|------------|--------|--------|
| Neuralink | High-density electrode array | Hippocampal prosthesis | Research |
| Various | DARPA's RAM Program | Memory prosthesis | Investigational |
| Karolinska Institute | Neural interface | Memory encoding | Research |

Alzheimer's-Specific Neurotech Pipeline

Clinical Trials in AD

| Company | Technology | Indication | Phase | NCT |
|---------|------------|------------|-------|-----|
| Medtronic | DBS (fornix) | AD/MCI | Phase 1 | NCT03295438 |
| Cognionics/UCSD | Closed-loop neurostimulation | AD | Pilot | NCT02827006 |
| Neuroelectrics | tDCS | AD | Phase 1 | NCT04334538 |

FDA Breakthrough Device Designations

• Neuralink N1 (2020) — Memory restoration
• Synchron Stentrode (2020) — Neural interface
• Medtronic DBS for AD — Memory enhancement
• NeuroPace RNS (expanded indication) — Cognitive monitoring

Investment and Funding

Notable Funding in Neurotech for AD

| Company | Funding | Year | Application |
|---------|---------|------|-------------|
| Neuralink | $680M (2024) | BCI, memory restoration |
| Synchron | $100M (2022) | Neural interface |
| Paradromics | $72M (2023) | Communication prosthetics |
| Precision Neuroscience | $93M (2023) | Cortical interface |

Market Projections

The neurotechnology market for Alzheimer's is projected to grow significantly:

• BCI devices for neurological disorders: $7-12B by 2030
• Neurostimulation devices for AD: $2-4B by 2030
• Non-invasive neuromodulation: $1-2B by 2030

Technology Comparison

Invasiveness Spectrum

| Technology | Invasiveness | Risk | Spatial Resolution | Temporal Resolution | AD Readiness |
|------------|---------------|------|---------------------|----------------------|--------------|
| Intracortical BCI | High | High | Excellent | Excellent | Research |
| DBS | High | Moderate | Good | Excellent | Investigational |
| ECoG | Moderate | Moderate | Good | Excellent | Research |
| TMS | Low | Low | Moderate | Good | Investigational |
| tDCS | Very Low | Very Low | Low | Good | Investigational |
| EEG | None | Minimal | Low | Good | Commercial |

Target Brain Regions for AD

| Target | Technology | Function |
|---------|------------|----------|
| Hippocampus | Invasive BCI, DBS | Memory encoding |
| Entorhinal cortex | Invasive BCI | Memory navigation |
| Nucleus basalis of Meynert | DBS | Cholinergic activation |
| Fornix | DBS | Memory circuits |
| Prefrontal cortex | TMS, tDCS | Cognitive control |

Regulatory Pathways

FDA Approval Pathways

Reimbursement

• DBS for Parkinson's is covered by Medicare
• Coverage for AD neurotech devices is under evaluation
• Current CPT codes: 0275T (DBS analysis), 95970 (neurostimulator programming)

Research Partnerships

Academic Collaborations

| Company | Institution | Focus |
|---------|-------------|-------|
| Medtronic | University of Pennsylvania | FORESTMEC trial |
| Neuralink | UCSF | Memory research |
| Synchron | Mt. Sinai | Neural interface |
| Boston Scientific | Cleveland Clinic | DBS optimization |

Government Funding

• NIH: BRAIN Initiative funding for neural interface development
• DARPA: RAM (Restoring Active Memory) program
• NSF: Neural engineering research

Cross-References

Related Technologies

• [Deep Brain Stimulation](/technologies/deep-brain-stimulation)
• [Transcranial Magnetic Stimulation](/technologies/transcranial-magnetic-stimulation)
• [Brain-Computer Interfaces](/technologies/brain-computer-interfaces)
• [Neuroprosthetics](/technologies/neuroprosthetics)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Related Treatments

• [Alzheimer's Disease Treatment Pipeline](/therapeutics/alzheimers-disease-treatment-pipeline)
• [Non-Pharmacological Therapies](/therapeutics/non-pharmacological-therapies)

See Also

• [BCI Companies](/companies/bci-companies) — Comprehensive BCI landscape
• [Parkinson's Neurotechnology](/companies/pd-neurotechnology) — Movement disorder devices
• [Medical Device Companies](/companies/medical-device-companies) — Device manufacturer overview

External Links

• [ClinicalTrials.gov — Neurotechnology AD trials](https://clinicaltrials.gov/)
• [FDA Breakthrough Devices Program](https://www.fda.gov/)
• [NIH BRAIN Initiative](https://braininitiative.nih.gov/)

References